DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Fundamental Analysis
NASDAQ:DVAX - US2681582019 - Common Stock
10.5 USD
-0.45 (-4.11%)
10.5001 USD
0 (0%)
Overall DVAX gets a fundamental rating of 5 out of 10. We evaluated DVAX against 549 industry peers in the Biotechnology industry. Both the profitability and the financial health of DVAX get a neutral evaluation. Nothing too spectacular is happening here. DVAX is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year DVAX was profitable.
DVAX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: DVAX reported negative net income in multiple years.
Of the past 5 years DVAX 4 years had a positive operating cash flow.
1.2 Ratios
DVAX has a Return On Assets of -6.35%. This is amongst the best in the industry. DVAX outperforms 86.52% of its industry peers.
DVAX's Return On Equity of -11.31% is amongst the best of the industry. DVAX outperforms 87.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.35% | ||
| ROE | -11.31% | ||
| ROIC | N/A |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DVAX's Profit Margin has declined in the last couple of years.
DVAX has a better Gross Margin (82.27%) than 85.97% of its industry peers.
In the last couple of years the Gross Margin of DVAX has grown nicely.
DVAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.27% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
2. Health
2.1 Basic Checks
DVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DVAX has been reduced compared to 1 year ago.
The number of shares outstanding for DVAX has been increased compared to 5 years ago.
The debt/assets ratio for DVAX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.65, we must say that DVAX is in the distress zone and has some risk of bankruptcy.
DVAX has a better Altman-Z score (1.65) than 69.22% of its industry peers.
DVAX has a debt to FCF ratio of 4.82. This is a neutral value as DVAX would need 4.82 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 4.82, DVAX belongs to the best of the industry, outperforming 92.90% of the companies in the same industry.
DVAX has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.49, DVAX is not doing good in the industry: 74.50% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.82 | ||
| Altman-Z | 1.65 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
DVAX has a Current Ratio of 11.93. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
DVAX's Current ratio of 11.93 is amongst the best of the industry. DVAX outperforms 84.15% of its industry peers.
A Quick Ratio of 10.84 indicates that DVAX has no problem at all paying its short term obligations.
DVAX has a better Quick ratio (10.84) than 82.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.93 | ||
| Quick Ratio | 10.84 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 186.36% over the past year.
DVAX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -19.10% yearly.
DVAX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.36%.
Measured over the past years, DVAX shows a very strong growth in Revenue. The Revenue has been growing by 51.10% on average per year.
EPS 1Y (TTM)186.36%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)19.36%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%29.33%
3.2 Future
DVAX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 61.35% yearly.
The Revenue is expected to grow by 15.25% on average over the next years. This is quite good.
EPS Next Y-332.47%
EPS Next 2Y73.55%
EPS Next 3Y61.35%
EPS Next 5YN/A
Revenue Next Year18.52%
Revenue Next 2Y17.67%
Revenue Next 3Y16.55%
Revenue Next 5Y15.25%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 32.81, DVAX can be considered very expensive at the moment.
92.17% of the companies in the same industry are more expensive than DVAX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of DVAX to the average of the S&P500 Index (27.24), we can say DVAX is valued slightly more expensively.
Based on the Price/Forward Earnings ratio of 19.37, the valuation of DVAX can be described as rather expensive.
DVAX's Price/Forward Earnings ratio is rather cheap when compared to the industry. DVAX is cheaper than 92.53% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.82, DVAX is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.81 | ||
| Fwd PE | 19.37 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, DVAX is valued cheaply inside the industry as 94.17% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.34 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DVAX's earnings are expected to grow with 61.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.55%
EPS Next 3Y61.35%
5. Dividend
5.1 Amount
DVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.5
-0.45 (-4.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners108.45%
Inst Owner Change-5.88%
Ins Owners0.55%
Ins Owner Change0.05%
Market Cap1.26B
Analysts80
Price Target24.3 (131.43%)
Short Float %12.14%
Short Ratio9.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-34.97%
Min EPS beat(2)-86.66%
Max EPS beat(2)16.71%
EPS beat(4)3
Avg EPS beat(4)-11.24%
Min EPS beat(4)-86.66%
Max EPS beat(4)21.41%
EPS beat(8)6
Avg EPS beat(8)91.96%
EPS beat(12)9
Avg EPS beat(12)84.56%
EPS beat(16)10
Avg EPS beat(16)32.97%
Revenue beat(2)0
Avg Revenue beat(2)-4.07%
Min Revenue beat(2)-4.19%
Max Revenue beat(2)-3.96%
Revenue beat(4)0
Avg Revenue beat(4)-4.79%
Min Revenue beat(4)-6.08%
Max Revenue beat(4)-3.96%
Revenue beat(8)3
Avg Revenue beat(8)1.24%
Revenue beat(12)7
Avg Revenue beat(12)8.29%
Revenue beat(16)9
Avg Revenue beat(16)10.65%
PT rev (1m)0%
PT rev (3m)-0.75%
EPS NQ rev (1m)5.24%
EPS NQ rev (3m)2.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-445.71%
Revenue NQ rev (1m)0.87%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.81 | ||
| Fwd PE | 19.37 | ||
| P/S | 4.28 | ||
| P/FCF | 23.34 | ||
| P/OCF | 19.84 | ||
| P/B | 2.37 | ||
| P/tB | 2.38 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.32
EY3.05%
EPS(NY)0.54
Fwd EY5.16%
FCF(TTM)0.45
FCFY4.28%
OCF(TTM)0.53
OCFY5.04%
SpS2.45
BVpS4.42
TBVpS4.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.35% | ||
| ROE | -11.31% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.27% | ||
| FCFM | 18.34% |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
F-Score5
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.82 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 117.09% | ||
| Cap/Sales | 3.24% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.93 | ||
| Quick Ratio | 10.84 | ||
| Altman-Z | 1.65 |
F-Score5
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)107.38%
Cap/Depr(5y)141.26%
Cap/Sales(3y)1.68%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)186.36%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-332.47%
EPS Next 2Y73.55%
EPS Next 3Y61.35%
EPS Next 5YN/A
Revenue 1Y (TTM)19.36%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%29.33%
Revenue Next Year18.52%
Revenue Next 2Y17.67%
Revenue Next 3Y16.55%
Revenue Next 5Y15.25%
EBIT growth 1Y56.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year356.6%
EBIT Next 3Y104.13%
EBIT Next 5YN/A
FCF growth 1Y-59.6%
FCF growth 3Y-43.07%
FCF growth 5YN/A
OCF growth 1Y-54.83%
OCF growth 3Y-41.69%
OCF growth 5YN/A